Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty

Franceschi, Roberto; Gaudino, Rossella; Marcolongo, Alma; Gallo, Maria Chiara; Rossi, Luigi; Antoniazzi, Franco; Tatò, Luciano

doi:10.1016/j.fertnstert.2008.11.016

Cited by 60 publications

(45 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Data from the literature are limited, and the criteria used for PCOS diagnosis are not uniform among studies. While Heger et al (22) observed a low incidence of PCOS (2%) based on Franks criteria, one study is supportive of the relationship between CPP and PCOS (48). In this cohort, which did not include a control group of untreated CPP girls, the prevalence of PCOS was 32% using the 2003 Rotterdam criteria and 30% using the Androgen Excess Society (AES) criteria.…”

Section: Reproductive Function and Risk Of Polycystic Ovarian Syndromementioning

confidence: 67%

“…Feuillan et al (40) described the ovarian volume larger than normal at 4-5 years post-treatment, whereas another study including adult CPP-treated women showed the ovarian volume within normal range (52). Ovarian volume O10 ml was observed in 20% of CPP-treated patients (49,50), a percentage similar to that found in age-matched, healthy controls (48). CPP patients with regular vs irregular menses showed no differences in the ovarian volume (22).…”

Section: Reproductive Function and Risk Of Polycystic Ovarian Syndromementioning

confidence: 86%

“…These findings suggest, according to the authors, a protective role for gonadotropin suppressive treatment on the reproductive outcome of CPP women. PCO morphology detected by ultrasound (US) was reported in 0-37% of treated CPP girls (median 2%) (21,36,46,47,48,49,50,51), with different lengths of posttreatment follow-up (up to 20 years), as summarized in Supplementary Table 4, see section on supplementary data given at the end of this article. Feuillan et al (40) described the ovarian volume larger than normal at 4-5 years post-treatment, whereas another study including adult CPP-treated women showed the ovarian volume within normal range (52).…”

Section: Reproductive Function and Risk Of Polycystic Ovarian Syndromementioning

confidence: 99%

See 2 more Smart Citations

MANAGEMENT OF ENDOCRINE DISEASE: Long-term outcomes of the treatment of central precocious puberty

Guaraldi

Beccuti

Gori

et al. 2016

European Journal of Endocrinology

115

View full text Add to dashboard Cite

GnRH analogues (GnRHa) are the treatment of choice for central precocious puberty (CPP), with the main objective to recover the height potential compromised by the premature fusion of growth cartilages. The aim of this review was to analyze longterm effects of GnRHa on height, body weight, reproductive function, and bone mineral density (BMD) in patients with CPP, as well as the potential predictors of outcome. Because randomized controlled trials on the effectiveness and long-term outcomes of treatment are not available, only qualified conclusions about the efficacy of interventions can be drawn. GnRHa treatment appears to improve adult height in girls with CPP, especially if diagnosed before the age of 6, whereas a real benefit in terms of adult height is still controversial in patients with the onset of puberty between 6 and 8 years of age. No height benefit was shown in patients treated after 8 years. Gonadal function is promptly restored in girls after cessation of treatment, and reproductive potential appears normal in young adulthood. Data are conflicting on the long-term risk of polycystic ovarian syndrome in both treated and untreated women. Fat mass is increased at the start of treatment but normalizes thereafter, and GnRHa itself does not seem to have any long-term effect on BMI. Similarly, analogue treatment does not appear to have a negative impact on BMD. Owing to the paucity of data available, no conclusions can be drawn on the repercussions of CPP and/or its treatment on the timing of menopause and on the health of the offspring.

show abstract

Section: Reproductive Function and Risk Of Polycystic Ovarian Syndromementioning

confidence: 67%

Section: Reproductive Function and Risk Of Polycystic Ovarian Syndromementioning

confidence: 86%

Section: Reproductive Function and Risk Of Polycystic Ovarian Syndromementioning

confidence: 99%

See 1 more Smart Citation

MANAGEMENT OF ENDOCRINE DISEASE: Long-term outcomes of the treatment of central precocious puberty

Guaraldi

Beccuti

Gori

et al. 2016

European Journal of Endocrinology

115

View full text Add to dashboard Cite

show abstract

“…Regular ovarian cycles occur in 60% to 96% of the patients, and infertility has not been reported (44,59). In females, an increased prevalence of polycystic ovary syndrome has been reported, although the findings are controversial (44,60). In males, a few studies that have been carried out have shown normal gonadal function (43).…”

Section: Long-term Follow-upmentioning

confidence: 99%

Central precocious puberty: revisiting the diagnosis and therapeutic management

Brito

Spinola-Castro

Kochi

et al. 2016

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain challenging due to lack of standardization. The aim of this revision was to address the diagnostic and therapeutic features of CPP in Brazil based on relevant international literature and availability of the existing therapies in the country. The diagnosis of CPP is based mainly on clinical and biochemical parameters, and a period of follow-up is desirable to define the "progressive" form of sexual precocity. This occurs due to the broad spectrum of pubertal development, including isolated premature thelarche, constitutional growth and puberty acceleration, progressive and nonprogressive CPP, and early puberty. Measurement of basal and stimulated LH levels remains challenging, considering that the levels are not always in the pubertal range at baseline, short-acting GnRH is not readily available in Brazil, and the cutoff values differ according to the laboratory assay. When CPP is suspected but basal LH values are at prepubertal range, a stimulation test with short-acting or long-acting monthly GnRH is a diagnostic option. In Brazil, the treatment of choice for progressive CPP and early puberty is a long-acting GnRH analog (GnRHa) administered once a month or every 3 months. In Brazil, formulations of GnRHa (leuprorelin and triptorelin) are available and commonly administered, including 1-month depot leuprorelin 3.75 mg and 7.5 mg, 1-month depot triptorelin 3.75 mg, and 3-month depot leuprorelin 11.25 mg. Monthly or 3-month depot GnRHa are effective and safe to treat CPP. Arch Endocrinol Metab. 2016;60(2):163-72

show abstract

“…A reversibilidade completa do eixo gonadotrófico após a interrupção do tratamento com a-GnRH foi demonstrada em alguns estudos (46). No sexo feminino, uma prevalência elevada de 30% a 32% de síndrome de ovários policísticos foi evidenciada em estudo italiano composto de 46 pacientes com seguimento por três anos após a menarca (47). O padrão dos ciclos menstruais foi normal na maioria dessas pacientes e o fenótipo caracterizou-se por hiperandrogenismo bioquímico e/ou clínico, associado à morfologia de ovários multipolicísticos.…”

Section: Tratamento Da Puberdade Precoce Centralunclassified

Avanços na etiologia, no diagnóstico e no tratamento da puberdade precoce central

Macedo

Cukier

Mendonca

et al. 2014

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOO início da puberdade caracteriza-se pelo aumento de amplitude e frequência dos pulsos do hormô-nio secretor de gonadotrofinas (GnRH) após um período de relativa supressão hormonal durante a infância. A reemergência da secreção pulsátil do GnRH resulta em aumento na secreção de gonadotrofinas, hormônio luteinizante (LH) e folículo estimulante (FSH), pela hipófise anterior e consequente ativação gonadal. A ativação prematura do eixo hipotálamo-hipófise-gonadal resulta em puberdade precoce dependente de gonadotrofinas, também conhecida como puberdade precoce central (PPC), e se caracteriza pelo desenvolvimento dos caracteres sexuais secundários antes dos 8 anos nas meninas e 9 anos nos meninos. O início do desenvolvimento puberal provém da interação complexa de fatores genéticos, nutricionais, ambientais e socioeconômicos. O diagnóstico clínico da PPC baseia-se em reconhecimento de desenvolvimento puberal progressivo, concentrações púberes de LH em condição basal e/ou após estímulo com GnRH e avanço de idade óssea. A ressonância magnética de encéfalo é útil no estabelecimento de diagnóstico diferencial entre as formas orgânica ou idiopática. Os análogos de GnRH de ação prolongada representam o tratamento de escolha da PPC. O componente genético da PPC foi recentemente fortalecido pela evidência de mutações no gene MKRN3, localizado no braço longo do cromossomo 15, em crianças com PPC familial. Nessa revisão, dados clínicos e terapêuticos da PPC serão amplamente discutidos, visando à atualização e à conduta criteriosa dessa condição clínica de grande relevância na endocrinologia pediátrica. Arq Bras Endocrinol Metab. 2014;58(2):108-17 Descritores Puberdade precoce central; hamartomas; mutação genética; gonadotrofinas; análogos de GnRH ABSTRACTThe onset of puberty is first detected as an increase in the amplitude and frequency of pulses of gonadotropin-releasing hormone (GnRH) after a quiescent period during childhood. The reemergence of pulsatile GnRH secretion leads to increases in the secretion of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) by the pituitary gland, and the consequent activation of gonadal function. Early activation of the hypothalamic-pituitary-gonadal axis results in gonadotropin-dependent precocious puberty, also known as central precocious puberty (CPP), which is clinically defined by the development of secondary sexual characteristics before the age of 8 years in girls and 9 years in boys. Pubertal timing is influenced by complex interactions among genetic, nutritional, environmental, and socioeconomic factors. CPP is diagnosed on the basis of clinical signs of progressive pubertal development before the age of 8 years in girls and 9 years in boys, pubertal basal and/or GnRH-stimulated LH levels, and advanced bone age. Magnetic resonance imaging of the central nervous system is essential for establishing the CPP form as organic or idiopathic. Depot GnRH-analogues represent the first-line of therapy in CPP. Very recently, the genetic component of CP...

show abstract

Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty

Cited by 60 publications

References 39 publications

MANAGEMENT OF ENDOCRINE DISEASE: Long-term outcomes of the treatment of central precocious puberty

MANAGEMENT OF ENDOCRINE DISEASE: Long-term outcomes of the treatment of central precocious puberty

Central precocious puberty: revisiting the diagnosis and therapeutic management

Avanços na etiologia, no diagnóstico e no tratamento da puberdade precoce central

Contact Info

Product

Resources

About